AMVUTTRA is an RNAi therapeutic indicated for the treatment of the polyneuropathy of hATTR amyloidosis in adults1
AMVUTTRA is a double-stranded small interfering RNA (siRNA) that is formulated for targeted delivery to hepatocytes, the primary source of TTR protein production.1-3
mRNA=messenger RNA; RNA=ribonucleic acid; RNAi=RNA interference.
AMVUTTRA uses an Enhanced Stabilization Chemistry-GalNAc conjugate designed for high metabolic stability, resulting in increased potency and prolonged duration of activity to allow infrequent dosing.1,6
Treatment with AMVUTTRA led to rapid, powerful, and sustained reduction in serum TTR7,8
aBars represent SEM (standard error of the mean).
aBars represent SEM (standard error of the mean).
- Serum TTR was evaluated in patients with hATTR amyloidosis with polyneuropathy treated with 25 mg AMVUTTRA via subcutaneous injection once every 3 months1
- Similar reduction in serum TTR was observed regardless of V30M variant status, prior TTR stabilizer use, sex, age, weight, or race1,10
AMVUTTRA is formulated to enable dosing via subcutaneous injection 4 times per year.1